Abstract
Purpose:The purpose of this study was to determine the prognostic information from mastectomy and axillary node dissection in patients with stage III-B breast cancer after down staging.
Materials and methods: Mastectomy and axillary dissection was performed for 97 patients with stage III-B breast cancer after downstaging. Estrogen receptor status, histologic type, median number of axillary lymph nodes, median number of positive axillary lymph nodes, positive lymph nodes / total lymph nodes ratio were analysed. Overall survival and disease free survival were determined for five years. Survival was calculated using the Cox regresion method.
Results: Median number of total axillary lymph nodes was 20,2; median number of metastatic axillary lymph nodes was 8,9; positive lymph nodes / total lymph nodes ratio was 0,44. Among the 80 patients (except 17 unknown receptor status) 35%were found to have estrogen receptor positive and 86 cases (%88,7) were invasive ductal cancer on pathologic examination of the axillary contents. Five year overall survival and disease free survival rates were %38,7 and %28 respectively.
Conclusion: Estrogen receptor status, ratio of positive axillary lymph nodes and inflammatory breast cancer effect 5 year survival rates after total mastectomy and axillary dissection.
Keywords:
Locally advanced (stage IIIB) breast cancer, axillary lymph node metastasis.
References
1Wolff C.A, Davidson N.E. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease The Oncologist 2002; 7: 239–245.
2Haagansen CD, Diseases of breast . Philadelphia ,WB Saunders, 1971.
3González-Vela MC, Garijo MF, Fernández FA, et al. Predictors of axillary lymph node metastases in patients with invasive breast carcinoma by a combination of classical and biological prognostic factors. Pathol Res Pract 1999;195:611-618.
4Kuijt GP, van de Poll-Franse LV, Voogd AC, et al. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection. Eur J Surg Oncol 2007 ; 33: 832-837.
5Amersi F, Hansen NM. The benefits and limitations of sentinel lymph node biopsy. Curr Treat Options Oncol 2006:141-151.
6Diaconu C, Gavrilovici V, et al. Combined modality treatment for locally advanced breast cancer. Acta Chir Belg 2003:589-592.
7Meric F, Mirza NQ, Buzdar AU et al. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol 2000 ;7 :435-440.
8Huang EH, Tucker SL, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 2005:351-357.
9Yildirim E, Berberoglu U. Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg 2007 ;31:276-289.
10Joslyn SA, Konety BR.Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat 2005; 91: 11-18.
11Favret AM, Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE. Locally advanced breast cancer: is surgery necessary? Breast J 2001: 7: 131-137.
12Gajdos C, Tartter PI, Estabrook A, et al. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002; 80: 4-11.
13Beenken SW, Urist MM, Zhang Y, Desmond R, Krontiras H, Medina H, Bland KI. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer Ann Surg. 2003; 237: 732-8; 738-739.
14Kuerer HM, Newman LA, Buzdar AU,et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998; 176: 502-509.
15Çam R. Meme kanserinde prognostik faktörler. Temel Cerrahi. Güneş Kitabevi 2004: 953-958.
16Özmen V. Meme kenserinde prognostik faktörler. Genel Cerrahi, Nobel Tıp Kitabevi. Cilt 1. 2002; 574-580.
17Sanchez-Forgach ER, Mamounas EP, et al. Factors affecting outcome in locally advanced breast cancer. Surg Oncol 1992; 1: 347-355.
18Singletary ES, Ames FC, Buzdar AU.Management of inflammatory breast cancer. World J Surg 1994; 18: 87–92.
19Walshe JM, Swain SM. Clinical aspects of inflammatory breast cancer. Breast Dis 2005–2006;22: 35–44.
20W. A. Woodward, E. A. Strom, M. D. McNeese et al. Changes to the 2002 AJCC (American Joint Commission of Cancer) staging system dramatically improve the stage-specific survival of breast cancer patients. 2003 ASCO Annual Meeting, Breast Cancer, Local-Regional Therapy, Abstract No: 17.
